BioCardia, Inc. Research and Development Expense
BioCardia, Inc. (BCDA) reported Research and Development Expense of $893.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-12
- BioCardia, Inc. research and development expense for the quarter ending 2026-06-30 was $893.00K, a 34.72% decline year-over-year.
- BioCardia, Inc. research and development expense for the quarter ending 2026-03-31 was $1.24M, a 19.28% decline year-over-year.
- BioCardia, Inc. research and development expense for the quarter ending 2025-12-31 was $1.13M, a 20.28% decline year-over-year.
- BioCardia, Inc. research and development expense for the quarter ending 2025-09-30 was $936.00K, a 0.54% increase year-over-year.
- BioCardia, Inc. research and development expense for fiscal 2025 was $4.96M, a 13.11% increase from fiscal 2024.
- BioCardia, Inc. research and development expense for fiscal 2024 was $4.39M, a 43.22% decline from fiscal 2023.
- BioCardia, Inc. research and development expense for fiscal 2023 was $7.73M, a 12.54% decline from fiscal 2022.
- BioCardia, Inc. research and development expense for fiscal 2022 was $8.83M, a 3.23% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $893.00K 10-Q · filed 2026-08-12 | $2.13M 10-Q · filed 2026-08-12 | $3.26M derived: sum of 3 quarters · filed 2026-08-12 | $4.19M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $1.24M 10-Q · filed 2026-05-15 | $2.36M derived: sum of 2 quarters · filed 2026-05-15 | $3.30M derived: sum of 3 quarters · filed 2026-05-15 | $4.67M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $1.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $2.06M derived: sum of 2 quarters · filed 2026-03-24 | $3.43M derived: sum of 3 quarters · filed 2026-08-12 | $4.96M 10-K · filed 2026-03-24 |
| 2025-09-30 | $936.00K 10-Q · filed 2025-11-12 | $2.30M derived: sum of 2 quarters · filed 2026-08-12 | $3.83M 10-Q · filed 2025-11-12 | $5.25M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $1.37M 10-Q · filed 2026-08-12 | $2.90M 10-Q · filed 2026-08-12 | $4.31M derived: sum of 3 quarters · filed 2026-08-12 | $5.24M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $1.53M 10-Q · filed 2026-05-15 | $2.94M derived: sum of 2 quarters · filed 2026-05-15 | $3.88M derived: sum of 3 quarters · filed 2026-05-15 | $4.68M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $1.42M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $2.35M derived: sum of 2 quarters · filed 2026-03-24 | $3.15M derived: sum of 3 quarters · filed 2026-03-24 | $4.39M 10-K · filed 2026-03-24 |
| 2024-09-30 | $931.00K 10-Q · filed 2025-11-12 | $1.73M derived: sum of 2 quarters · filed 2025-11-12 | $2.97M 10-Q · filed 2025-11-12 | $4.13M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $800.00K 10-Q/A · filed 2025-10-29 | $2.04M 10-Q/A · filed 2025-10-29 | $3.20M derived: sum of 3 quarters · filed 2025-10-29 | $5.07M derived: sum of 4 quarters · filed 2025-10-29 |
| 2024-03-31 | $1.24M 10-Q · filed 2025-05-14 | $2.40M derived: sum of 2 quarters · filed 2025-05-14 | $4.27M derived: sum of 3 quarters · filed 2025-05-14 | $6.58M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $1.16M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-26 | $3.03M derived: sum of 2 quarters · filed 2025-03-26 | $5.34M derived: sum of 3 quarters · filed 2025-03-26 | $7.73M 10-K · filed 2025-03-26 |
| 2023-09-30 | $1.87M 10-Q · filed 2024-11-13 | $4.19M derived: sum of 2 quarters · filed 2024-11-13 | $6.57M 10-Q · filed 2024-11-13 | $8.77M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $2.31M 10-Q · filed 2024-08-13 | $4.70M 10-Q · filed 2024-08-13 | $6.90M derived: sum of 3 quarters · filed 2024-08-13 | $9.04M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $2.38M 10-Q · filed 2024-05-14 | $4.58M derived: sum of 2 quarters · filed 2024-05-14 | $6.73M derived: sum of 3 quarters · filed 2024-05-14 | $9.03M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $2.20M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | $4.34M derived: sum of 2 quarters · filed 2024-03-27 | $6.65M derived: sum of 3 quarters · filed 2024-03-27 | $8.83M 10-K · filed 2024-03-27 |
| 2022-09-30 | $2.14M 10-Q · filed 2023-11-08 | $4.45M derived: sum of 2 quarters · filed 2023-11-08 | $6.63M 10-Q · filed 2023-11-08 | $8.75M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | $2.30M 10-Q · filed 2023-08-09 | $4.49M 10-Q · filed 2023-08-09 | $6.61M derived: sum of 3 quarters · filed 2023-08-09 | $8.85M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $2.19M 10-Q · filed 2023-05-10 | $4.30M derived: sum of 2 quarters · filed 2023-05-10 | $6.54M derived: sum of 3 quarters · filed 2023-05-10 | $8.90M derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | $2.12M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $4.36M derived: sum of 2 quarters · filed 2023-03-29 | $6.72M derived: sum of 3 quarters · filed 2023-03-29 | $8.56M 10-K · filed 2023-03-29 |
| 2021-09-30 | $2.24M 10-Q · filed 2022-11-09 | $4.60M derived: sum of 2 quarters · filed 2022-11-09 | $6.44M 10-Q · filed 2022-11-09 | $8.77M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $2.36M 10-Q · filed 2022-08-10 | $4.20M 10-Q · filed 2022-08-10 | $6.53M derived: sum of 3 quarters · filed 2022-08-10 | $9.00M derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | $1.84M 10-Q · filed 2022-05-11 | $4.17M derived: sum of 2 quarters · filed 2022-05-11 | $6.64M derived: sum of 3 quarters · filed 2022-05-11 | $8.86M derived: sum of 4 quarters · filed 2022-05-11 |
| 2020-12-31 | $2.33M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | $4.80M derived: sum of 2 quarters · filed 2022-03-29 | $7.02M derived: sum of 3 quarters · filed 2022-03-29 | $9.81M 10-K · filed 2022-03-29 |
| 2020-09-30 | $2.47M 10-Q · filed 2021-11-10 | $4.70M derived: sum of 2 quarters · filed 2021-11-10 | $7.48M 10-Q · filed 2021-11-10 | $9.65M derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | $2.22M 10-Q · filed 2021-08-12 | $5.01M 10-Q · filed 2021-08-12 | $7.18M derived: sum of 3 quarters · filed 2021-08-12 | $9.19M derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | $2.79M 10-Q · filed 2021-05-13 | $4.96M derived: sum of 2 quarters · filed 2021-05-13 | $6.96M derived: sum of 3 quarters · filed 2021-05-13 | $9.18M derived: sum of 4 quarters · filed 2021-05-13 |
| 2019-12-31 | $2.17M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-30 | $4.18M derived: sum of 2 quarters · filed 2021-03-30 | $6.40M derived: sum of 3 quarters · filed 2021-03-30 | $8.56M 10-K · filed 2021-03-30 |
| 2019-09-30 | $2.01M 10-Q · filed 2020-11-10 | $4.23M derived: sum of 2 quarters · filed 2020-11-10 | $6.39M 10-Q · filed 2020-11-10 | $8.60M derived: sum of 4 quarters · filed 2020-11-10 |
| 2019-06-30 | $2.22M 10-Q · filed 2020-08-13 | $4.38M 10-Q · filed 2020-08-13 | $6.59M derived: sum of 3 quarters · filed 2020-08-13 | $8.85M derived: sum of 4 quarters · filed 2020-08-13 |
| 2019-03-31 | $2.17M 10-Q · filed 2020-05-15 | $4.37M derived: sum of 2 quarters · filed 2020-05-15 | $6.63M derived: sum of 3 quarters · filed 2020-05-15 | $8.66M derived: sum of 4 quarters · filed 2020-05-15 |
| 2018-12-31 | $2.21M derived: 10-K 12 month − 10-Q 9 month · filed 2020-04-09 | $4.47M derived: sum of 2 quarters · filed 2020-04-09 | $6.50M derived: sum of 3 quarters · filed 2020-04-09 | $8.45M 10-K · filed 2020-04-09 |
| 2018-09-30 | $2.26M 10-Q · filed 2019-11-19 | $4.29M derived: sum of 2 quarters · filed 2019-11-19 | $6.25M 10-Q · filed 2019-11-19 | $8.02M derived: sum of 4 quarters · filed 2020-04-09 |
| 2018-06-30 | $2.03M 10-Q · filed 2019-08-14 | $3.99M 10-Q · filed 2019-08-14 | $5.76M derived: sum of 3 quarters · filed 2020-04-09 | $7.46M derived: sum of 4 quarters · filed 2020-04-09 |
| 2018-03-31 | $1.96M 10-Q · filed 2019-05-15 | $3.73M derived: sum of 2 quarters · filed 2020-04-09 | $5.43M derived: sum of 3 quarters · filed 2020-04-09 | $6.72M derived: sum of 4 quarters · filed 2020-04-09 |
| 2017-12-31 | $1.77M derived: 10-K 12 month − 10-Q 9 month · filed 2020-04-09 | $3.47M derived: sum of 2 quarters · filed 2020-04-09 | $4.77M derived: sum of 3 quarters · filed 2020-04-09 | $5.80M 10-K · filed 2020-04-09 |
| 2017-09-30 | $1.70M 10-Q · filed 2018-11-08 | $3.00M derived: sum of 2 quarters · filed 2018-11-08 | $4.03M 10-Q · filed 2018-11-08 | $5.74M derived: sum of 4 quarters · filed 2019-04-02 |
| 2017-06-30 | $1.29M 10-Q · filed 2018-08-09 | $2.33M 10-Q · filed 2018-08-09 | $4.04M derived: sum of 3 quarters · filed 2019-04-02 | $4.72M derived: sum of 4 quarters · filed 2019-04-02 |
| 2017-03-31 | $1.03M 10-Q · filed 2018-05-10 | $2.74M derived: sum of 2 quarters · filed 2019-04-02 | $3.42M derived: sum of 3 quarters · filed 2019-04-02 | $3.92M derived: sum of 4 quarters · filed 2019-04-02 |
| 2016-12-31 | $1.71M derived: 10-K 12 month − 10-Q 9 month · filed 2019-04-02 | $2.39M derived: sum of 2 quarters · filed 2019-04-02 | $2.89M derived: sum of 3 quarters · filed 2019-04-02 | $3.33M 10-K · filed 2019-04-02 |
| 2016-09-30 | $684.00K 10-Q · filed 2017-11-09 | $1.18M derived: sum of 2 quarters · filed 2017-11-09 | $1.62M 10-Q · filed 2017-11-09 | |
| 2016-06-30 | $497.00K 10-Q · filed 2017-08-14 | $938.00K 10-Q · filed 2017-08-14 | ||
| 2016-03-31 | $441.00K 10-Q · filed 2017-05-11 | |||
| 2015-12-31 | $1.52M 10-K · filed 2018-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |